Parkinson’s patients will receive cannabis oil in a “pioneering” clinical trial that aims to demonstrate the benefits, safety and efficacy of the treatment to help with hallucinations and delusions, two frightening symptoms of the disease.

Parkinson’s UK said the trial is particularly important as an increasing number of people are using expensive and unregulated cannabis oil, or CBD, supplements that have not been monitored for their effectiveness. The charity is partnering with King’s College London and investing £1.2m in the trial.

See the original article at MSN